---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027639"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:12:03.930286+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Director resigns citing governance concerns; Bioxytran hires independent expert for controls review

## Summary
- Anders Utter resigns from Bioxytran's Board and Audit Committee chair, effective Dec 7, 2025, citing need for enhanced oversight and controls.
- Utter's recommendations included strengthening segregation of duties, improving financial approval documentation, and legal review of a recent stock issuance.
- Company engages an independent third-party financial expert to review oversight, internal controls, and approval processes.
- No disagreement related to financial statements, accounting practices, or SEC disclosures, per filing.

## SEC filing metadata
- accession: 0001493152-25-027639
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315225027639/0001493152-25-027639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315225027639/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027639
- JSON: https://secwatch.observer/filing/0001493152-25-027639.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.